Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03.
Cabioglu N, Karanlik H, Igci A, Muslumanoglu M, Gulcelik MA, Uras C, Kocer HB, Trabulus DC, Ozkurt E, Cakmak GK, Tukenmez M, Bademler S, Yildirim N, Akgul GG, Sen E, Senol K, Emiroglu S, Citgez B, Ersoy YE, Dag A, Zengel B, Basaran G, Kara H, Dilege E, Ugurlu MU, Celik A, Ilgun S, Bolukbasi Y, Karaman N, Sakman G, Ozbas S, Kilic HG, Polat AK, Ozemir IA, Kilic B, Altınok A, Varol E, Dogan L, Akcan A, Ozcinar B, Zer L, Soyder A, Velidedeoglu M, Erozgen F, Goktepe B, Dogan M, Kebudi A, Yigit B, Celik B, Yormaz S, Arici C, Agcaoglu O, Sevinc AI, Atahan MK, Valiyeva V, Baran E, Aljorani I, Utkan Z, Yeniay L, Kivilcim T, Soran A, Aydiner A, Ibis K, Ozmen V. Cabioglu N, et al. Among authors: zer l. Ann Surg Oncol. 2024 Dec 2. doi: 10.1245/s10434-024-16472-6. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39623189
Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided.
Muslumanoglu M, Cabioglu N, Igci A, Karanlık H, Kocer HB, Senol K, Mantoglu B, Tukenmez M, Çakmak GK, Ozkurt E, Gulcelik MA, Emiroglu S, Mollavelioglu B, Yildirim N, Bademler S, Zengel B, Trabulus DC, Ugurlu MU, Uras C, Ilgun S, Akgul GG, Akcan A, Yormaz S, Ersoy YE, Ozbas S, Dilege E, Citgez B, Bolukbasi Y, Altınok A, Dag A, Basaran G, Utkan NZ, Ozcinar B, Arici C, AlJorani I, Kara H, Yigit B, Sen E, Erozgen F, Soyder A, Celik B, Kilic HG, Zer L, Sakman G, Yeniay L, Atahan K, Varol E, Veliyeva V, Goktepe B, Velidedeoglu M, Karaman N, Soran A, Aydiner A, Yılmaz R, Ibis K, Ozmen V. Muslumanoglu M, et al. Among authors: zer l. Cancer. 2024 Oct 30. doi: 10.1002/cncr.35610. Online ahead of print. Cancer. 2024. PMID: 39476303